跳至主要内容
临床试验/NCT00562055
NCT00562055撤回2 期

Phase 2, Randomized, Double-Blind, Parallel-Group, Four Week, Efficacy And Safety Trial Of [S,S]-Reboxetine (PNU-165442g) And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Pfizer0 个研究点开始时间: 2007年11月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
撤回
发起方
Pfizer
主要终点
Adult ADHD Investigator Symptom Rating Scale - Total Score

研究概览

简要总结

This study will compare the safety and efficacy of [S,S]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria.
  • Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale
  • Score of 4 or higher on the Clinician Global Impression - Severity scale

排除标准

  • Significant comorbid psychiatric diagnoses
  • Significant risk of suicidal or violent behavior

研究组 & 干预措施

Arm A

Experimental

干预措施: PNU-165442G; [S,S]-reboxetine (Drug)

Arm B

Active Comparator

干预措施: Atomoxetine (Drug)

结局指标

主要结局

Adult ADHD Investigator Symptom Rating Scale - Total Score

时间窗: 4 weeks

次要结局

  • Adult ADHD Investigator Symptom Rating Scale - Hyperactivity/Impulsivity Subscale Score(4 weeks)
  • Adult ADHD Investigator Symptom Rating Scale - Inattention Subscale Score(4 weeks)

研究者

发起方
Pfizer
申办方类型
Industry

相似试验

Double-Blind, Four Week Trial Of [S,S]-Reboxetine... | 临床试验